查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区伴同性诊断市场：按技术、按应用、按最终用户、按国家 - 分析和预测（2023-2033 年）
市场调查报告书
商品编码
1585128

亚太地区伴同性诊断市场：按技术、按应用、按最终用户、按国家 - 分析和预测（2023-2033 年）

Asia-Pacific Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 73 Pages | 商品交期: 1-5个工作天内

价格

2023 年，亚太地区伴同性诊断市场价值为 7.337 亿美元。

预计2023年至2033年该市场将以14.53%的复合年增长率成长，2033年达到28.497亿美元。由于伴同性诊断工具的核准不断增加、生物医学影像的改进以及癌症发病率的上升，亚太地区伴同性诊断市场正在不断增长。这些是亚太地区在个人化癌症护理中越来越多地使用精准医疗和伴同性诊断的关键驱动因素。

主要市场统计数据
预测期 2023-2033
2023年评估 7.337 亿美元
2033 年预测 28.497 亿美元
复合年增长率 14.53%

由于对个人化治疗的需求不断增长以及慢性病（尤其是癌症）的盛行率上升，亚太地区的伴同性诊断市场预计将出现显着发展。为了提供更专业、更有效的治疗选择，伴同性诊断是帮助识别最有可能从特定药物中受益的患者的重要工具。随着该地区癌症发病率的增加以及对精准治疗的关注的增加，伴同性诊断变得越来越重要。

此外，检测开发和生物标记发现的技术发展也在推动市场。基因组和分子测试技术的进步导致与各种疾病相关的生物标记的发现，使得开发客製化治疗方法变得更加容易。此外，鼓励性的法律体制、製药公司增加研发资金也有助于市场扩张。

引入伴同性诊断的主要企业是中国、印度和日本，这些国家的生物製药公司和诊断公司之间有许多合作。随着患者和医疗保健专业人员越来越意识到个人化医疗的好处，亚太地区伴同性诊断市场预计将扩大，为医疗保健生态系统中的所有相关人员提供巨大的潜力。

该报告研究了亚太地区伴同性诊断市场，并提供了市场概述，包括按技术、应用、最终用户、国家/地区以及参与市场的公司概况分類的趋势。

目录

执行摘要

第一章 市场

  • 趋势：当前和未来的影响评估
  • 供应链概览
  • 研究发展回顾
  • 监管状况
  • 从历史角度进行伴同性诊断
  • 伴同性诊断 (CDx) 开发的组成部分
  • 伴同性诊断 (CDx)：未来的可能性
  • 市场动态概览

第二章 区域

  • 区域概况
  • 促进因素和抑制因素
  • 亚太地区

第三章市场－竞争基准化分析与公司概况

  • 未来展望
  • 地理评估
    • Amoy Diagnostics Co., Ltd.
    • Novogene Co, Ltd.
    • Sysmex Corporation

第四章调查方法

Product Code: BHP2385SS

Introduction to Asia-Pacific Companion Diagnostics Market

The Asia-Pacific companion diagnostics market was valued at $733.7 million in 2023 and is expected to reach $2,849.7 million by 2033, growing at a CAGR of 14.53% between 2023 and 2033. The Asia-Pacific (APAC) companion diagnostics market is growing as a result of increased approvals for companion diagnostic tools, improvements in biomedical imaging, and the rising incidence of cancer. These are the main causes of the increasing use of precision medicine and companion diagnostics in APAC's individualized cancer treatment.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$733.7 Million
2033 Forecast$2,849.7 Million
CAGR14.53%

The market for companion diagnostics in Asia-Pacific (APAC) is expected to develop significantly due to the increased need for personalized therapy and the rising prevalence of chronic diseases, especially cancer. In order to provide more specialized and efficient treatment options, companion diagnostics are crucial instruments that assist in identifying patients who are most likely to benefit from particular medicines. Companion diagnostics are becoming more and more important as the region sees an increase in cancer incidence and a greater focus on precision treatment.

The market is also being driven ahead by technological developments in assay development and biomarker discovery. The development of customized treatments is made easier by the discovery of biomarkers linked to a variety of diseases thanks to advancements in genomic and molecular testing technology. Furthermore, encouraging legal frameworks, more funding for research and development by pharmaceutical companies are contributing to the market's expansion.

Leading the way in the adoption of companion diagnostics are nations like China, India, and Japan, where biopharmaceutical businesses and diagnostic companies have partnered in large numbers. The APAC companion diagnostic market is expected to increase as patients and healthcare professionals become more aware of the advantages of personalized medicine, providing substantial potential for all parties involved in the healthcare ecosystem.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)
  • Others

Segmentation 2: by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Stomach Cancer
  • Melanoma
  • Others

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Reference Laboratories and Hospitals
  • Others

Segmentation 4: by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Amoy Diagnostics Co., Ltd.
  • Novogene Co, Ltd.
  • Sysmex Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Companion Diagnostics Market Trend Analysis
    • 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
    • 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Legal Requirements and Framework by the FDA
    • 1.4.2 Legal Requirements and Framework by the MHLW
  • 1.5 CDx from a Historical Perspective
  • 1.6 Constituents for Companion Diagnostics (CDx) Development
  • 1.7 Companion Diagnostics (CDx): Future Potential
  • 1.8 Market Dynamics Overview
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Cancer Cases
      • 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
      • 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
    • 1.8.2 Market Restraints
      • 1.8.2.1 Uncertain Reimbursement Scenario
      • 1.8.2.2 Stringent Regulatory Approval Processes
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
      • 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

2 Regions

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Asia-Pacific
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 China
    • 2.3.7 Application
    • 2.3.8 Product
    • 2.3.9 India
    • 2.3.10 Application
    • 2.3.11 Product
    • 2.3.12 Australia
    • 2.3.13 Application
    • 2.3.14 Product
    • 2.3.15 Japan
    • 2.3.16 Application
    • 2.3.17 Product
    • 2.3.18 South Korea
    • 2.3.19 Application
    • 2.3.20 Product
    • 2.3.21 Rest-of-Asia-Pacific
    • 2.3.22 Application
    • 2.3.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers.....
  • 3.2 Geographic Assessment
    • 3.2.1 Amoy Diagnostics Co., Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Novogene Co, Ltd.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Sysmex Corporation
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Asia-Pacific Companion Diagnostics Market, $Million, 2023, 2026, and 2033
  • Figure 2: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 4: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
  • Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
  • Figure 7: Applications of Digital Diagnostics
  • Figure 8: Supply Chain and Risks within the Supply Chain
  • Figure 9: Companion Diagnostics Market (by Country), January 2021-December 2023
  • Figure 10: Companion Diagnostics (by Year), January 2021-December 2023
  • Figure 11: Evolution of Companion Diagnostics
  • Figure 12: Components Required to Develop Companion Diagnostics
  • Figure 13: Future Prospects of CDx
  • Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
  • Figure 15: Factors Impacting Reimbursement Scenario
  • Figure 16: Advancements in Companion Diagnostics
  • Figure 17: Future Outlook of Epigenomics
  • Figure 18: Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 19: China Companion Diagnostics Market, $Million, 2022-2033
  • Figure 20: India Companion Diagnostics Market, $Million, 2022-2033
  • Figure 21: Australia Companion Diagnostics Market, $Million, 2022-2033
  • Figure 22: Japan Companion Diagnostics Market, $Million, 2022-2033
  • Figure 23: South Korea Companion Diagnostics Market, $Million, 2022-2033
  • Figure 24: Rest-of-Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 25: Strategic Initiatives, 2021-2023
  • Figure 26: Share of Strategic Initiatives, 2021-2023
  • Figure 27: Data Triangulation
  • Figure 28: Top-Down and Bottom-Up Approach
  • Figure 29: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Companion Diagnostics Market, Opportunities
  • Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
  • Table 4: Cancer Cases Expected between 2020 and 2040
  • Table 5: Product Approvals in the Field of Companion Diagnostics
  • Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
  • Table 7: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 8: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 9: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 10: China Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 11: China Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 12: China Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 13: India Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 14: India Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 15: India Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 16: Australia Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 17: Australia Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 18: Australia Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 19: Japan Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 20: Japan Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 21: Japan Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 22: South Korea Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 23: South Korea Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 24: South Korea Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 25: Rest-of-Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 26: Rest-of-Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 27: Rest-of-Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033